DOCSLIB.ORG

Glucocorticoid Enhancement of Memory Storage Involves

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glucocorticoid Enhancement of Memory Storage Involves Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14048–14053, December 1997 Neurobiology Glucocorticoid enhancement of memory storage involves noradrenergic activation in the basolateral amygdala (dexamethasoneyRU 28362yb-adrenergic antagonistsyinhibitory avoidance) GINA L. QUIRARTE*†,BENNO ROOZENDAAL*‡, AND JAMES L. MCGAUGH*§ *Center for the Neurobiology of Learning and Memory and §Department of Psychobiology, University of California, Irvine, CA 92697-3800; and †Centro de Neurobiologı´a, Universitat Nacional Autonome de Mexico, Queretaro, Qro., 76001 Mexico Contributed by James L. McGaugh, October 7, 1997 ABSTRACT Evidence indicates that the modulatory ef- and opioid peptidergic systems influence the training-induced fects of the adrenergic stress hormone epinephrine as well as release of norepinephrine (13, 14). several other neuromodulatory systems on memory storage Findings of a series of recent experiments from our labo- are mediated by activation of b-adrenergic mechanisms in the ratory indicate that the amygdala is involved in mediating the amygdala. In view of our recent findings indicating that the memory-modulating effects of glucocorticoids (15). Excito- amygdala is involved in mediating the effects of glucocorti- toxically induced lesions of the basolateral (BLA), but not the coids on memory storage, the present study examined whether central (CEA), nucleus of the amygdala blocked the enhancing the glucocorticoid-induced effects on memory storage depend effects of systemic posttraining injections of dexamethasone, a on b-adrenergic activation within the amygdala. Microinfu- synthetic glucocorticoid, on memory for inhibitory avoidance sions (0.5 mgin0.2ml) of either propranolol (a nonspecific training (16). Furthermore, infusions of the specific glucocor- b b -adrenergic antagonist), atenolol (a 1-adrenergic antago- ticoid receptor (GR or type II) agonist RU 28362 (11b,17b- b nist), or zinterol (a 2-adrenergic antagonist) administered dihydroxy-6,21-dimethyl-17a-pregna-4,6-trien-20yn-3-one) bilaterally into the basolateral nucleus of the amygdala (BLA) into the BLA enhanced memory storage (17). Such findings of male Sprague–Dawley rats 10 min before training blocked suggest that glucocorticoid effects on memory storage are the enhancing effect of posttraining systemic injections of mediated, at least in part, by GRs in the BLA. Although the y dexamethasone (0.3 mg kg) on 48-h memory for inhibitory specific mode of action of glucocorticoids differs from that of b avoidance training. Infusions of these -adrenergic antago- the hormones and neurotransmitters just described (i.e., glu- nists into the central nucleus of the amygdala did not block the cocorticoids are highly lipophylic and bind directly to intra- dexamethasone-induced memory enhancement. Furthermore, cellular receptors in the brain), the involvement of the amyg- m atenolol (0.5 g) blocked the memory-enhancing effects of the dala in mediating the effects of all these compounds appears specific glucocorticoid receptor (GR or type II) agonist RU to be strikingly similar. These findings suggest that glucocor- 28362 infused concurrently into the BLA immediately post- ticoid-induced effects on memory storage may also depend on b training. These results strongly suggest that -adrenergic intact noradrenergic neurotransmission in the amygdala. In activation is an essential step in mediating glucocorticoid support of this view, there is extensive evidence from bio- effects on memory storage and that the BLA is a locus of chemical and electrophysiological experiments indicating in- interaction for these two systems. teractions between glucocorticoids and the noradrenergic system in several brain structures, including the hypothalamus, Extensive evidence from studies of memory of inhibitory hippocampus, and cerebral cortex (18, 19). avoidance training in rats indicates that several neuromodu- The present study examined the involvement of b- latory systems interact with the noradrenergic system in the adrenoceptors in the amygdala in the modulating effects of amygdala in modulating memory storage (1–8). Intra- glucocorticoids on memory storage. In a first experiment, rats b amygdala infusions of the -adrenergic antagonist propranolol received microinfusions of b-adrenergic antagonists with ei- b b or depletion of norepinephrine in the amygdala by the neu- ther a selective affinity for 1-or 2-adrenoceptors or with a rotoxin N-2-chloroethyl-N-ethyl-bromobenzylamine (DSP-4) nonspecific affinity for both receptor types into the BLA or block the memory-enhancing effect of the adrenergic stress CEA before training in an inhibitory avoidance task. Dexa- hormone epinephrine (5, 6). Moreover, intra-amygdala infu- methasone was injected subcutaneously immediately after b b sions of propranolol as well as specific 1-or 2-adrenergic training. In a second experiment, rats received concurrent antagonists also block the effects, on memory, of drugs b immediate posttraining infusions of the 1-adrenergic antag- affecting opioid peptidergic and GABAergic systems (4, 7). b onist atenolol and the specific GR agonist RU 28362 into the Norepinephrine and other -adrenergic agonists administered BLA. In both experiments the animals were tested on retention to the amygdala after training dose-dependently enhance 48 h after training. retention (5, 9–11). These effects are also time-dependent; they affect retention when given shortly after training but have no effect if given several hours later. These findings are MATERIALS AND METHODS consistent with evidence from recent experiments using in vivo Subjects. Male Sprague–Dawley rats (270–300 g at time of microdialysis indicating that norepinephrine is released in the surgery) from Charles River Laboratories were used. They amygdala by footshock stimulation of the kind typically used in were individually housed in a temperature-controlled (22°C) inhibitory avoidance training (12). Furthermore, adrenergic colony room and maintained on a standard 12-h lighty12-h dark cycle (0700–1900 h lights on) with food and water The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ‘‘advertisement’’ in Abbreviations: BLA, basolateral amygdala; CEA, central amygdala; accordance with 18 U.S.C. §1734 solely to indicate this fact. GR, glucocorticoid receptor; RU 28362, 11b,17b-dihydroxy-6,21- © 1997 by The National Academy of Sciences 0027-8424y97y9414048-6$2.00y0 dimethyl-17a-pregna-4,6-trien-20yn-3-one. PNAS is available online at http:yywww.pnas.org. ‡To whom reprint requests should be addressed. 14048 Downloaded by guest on September 23, 2021 Neurobiology: Quirarte et al. Proc. Natl. Acad. Sci. USA 94 (1997) 14049 available ad libitum. Training and testing were performed delivered. For the animals given pretraining infusions of drug between 1000 and 1500 h. or control solution into the BLA, the footshock level used was Surgery. The animals were adapted to the vivarium for at 0.45 mA with a duration of 1 s. Preliminary data revealed that least 1 week before surgery. They were anesthetized with comparable retention latencies in CEA-infused animals were sodium pentobarbital (50 mgykg of body weight, i.p.) and given obtained with a slightly lower footshock intensity. Therefore, atropine sulfate (0.4 mgykg, i.p.). The skull was fixed to a CEA-infused animals received a footshock intensity of 0.40 stereotaxic frame (Kopf Instruments, Tujunga, CA), and mA for 1 s. The animals were removed from the shock stainless-steel guide cannulae (15 mm; 23 gauge) were im- compartment 15 s after termination of the footshock and, after planted bilaterally with the cannula tips 2 mm above the BLA drug treatment, returned to their home cages. On the retention [coordinates: anteroposterior (AP), 22.8 mm from bregma; test 48 h after training, the rat was placed in the starting mediolateral (ML), 65.0 mm from midline; dorsoventral compartment, as in the training session, and the latency to (DV), 26.5 mm from skull surface] or CEA [coordinates: AP, re-enter the dark compartment (maximum latency of 600 s) 22.2 mm; ML, 64.3 mm; DV, 26.0 mm] according to the atlas was recorded. Longer latencies were interpreted as indicating of Paxinos and Watson (20). The cannulas and two anchoring better retention. Shock was not administered on the retention screws were affixed to the skull with dental cement. Stylets (15 test trial. mm long 00 insect dissection pins) were inserted into the Histology. The rats were anesthetized with an overdose of cannulae to maintain patency and were removed only for the sodium pentobarbital (100 mgykg, i.p.) and perfused intra- infusion of drugs. The rats were allowed to recover 7 days cardially with a 0.9% saline solution followed by 10% form- before training and were handled three times for 1 min during aldehyde (volyvol). Following decapitation, the brains were this recovery period. removed and placed in 10% formaldehyde. At least 24 h before Drugs and Infusion Procedures. The nonspecific b- sectioning, the brains were submerged in a 20% sucrose adrenergic antagonist dl-propranolol (0.5 mg per side; Sigma) solution (wtyvol) for cryoprotection. Sections of 40 mm were b b m or the specific 1-or 2-adrenergic antagonists atenolol (0.5 g made (using a freezing microtome) and stained with cresyl per side; Sigma) or zinterol (0.5 mg per side; Bristol-Myers), violet. The sections were examined under a light microscope. respectively, were dissolved in 0.9% saline and infused either Determination of the
Load more

Recommended publications
  • Modulation of Dialysate Levels of Dopamine, Noradrenaline
    Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles b of -Adrenergic, 5-HT1A, and 5-HT1B Receptors Alain Gobert, Ph.D. and Mark J. Millan, Ph.D. (-)-Pindolol, which possesses significant affinity for 5-HT1A, involved. (-)-Pindolol potentiated the increase in FCX levels b 5-HT1B, and 1/2-adrenergic receptors (AR)s, dose- of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine dependently increased extracellular levels of dopamine and duloxetine, and also enhanced their ability to elevate (DA) and noradrenaline (NAD) versus 5-HT, in dialysates FCX levels of DA—though not of NAD. In contrast to of the frontal cortex (FCX), but not accumbens and (-)-pindolol, betaxolol and ICI118,551 did not affect the striatum, of freely-moving rats. In distinction, the actions of fluoxetine, whereas both WAY100,635 and b preferential 1-AR antagonist, betaxolol, and the SB224,289 potentiated the increase in levels of 5-HT—but b preferential 2-AR antagonist, ICI118,551, did not increase not DA or NAD levels—elicited by fluoxetine. In basal levels of DA, NAD, or 5-HT. Further, they both dose- conclusion, (-)-pindolol modulates, both alone and together dependently and markedly blunted the influence of with 5-HT reuptake inhibitors, dopaminergic, adrenergic, (-)-pindolol upon DA and NAD levels. The selective 5-HT1A and serotonergic transmission in the FCX via a complex b receptor antagonist, WAY100,635, slightly attenuated the pattern of actions at 1/2-ARs, 5-HT1A, and 5-HT1B (-)-pindolol-induced increase in DA and NAD levels, while receptors.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Cap11 Adrenolitico
    SECCION II: CAPITULO 11 DROGAS SIMPATICOLITICAS O ADRENOLITICAS Malgor - Valsecia Como anteriormente se mencionara, el siste- Son un grupo de drogas que actúan en la ter- ma Simpático o Adrenérgico cumple num ero- minación adrenérgica, a nivel axoplasmático o sas e importantísimas funciones biológicas sobre receptores presinápticos alfa2, salvo indispensables para la modulación y regula- estos últimos agentes, los adrenolíticos presi- ción de organismos y sistemas que son vitales nápticos tienen ac tualmente un uso clínico para el mantenimiento de una vida normal. terapéutico limitado. CLASIFICACIÓN DE DROGAS SIMPATICO- Las drogas simpaticolíticas o adrenolíticas LÍTICAS son un grupo numeroso de fármacos que in- terfieren con las funciones del sistema simpá- I.SIMPATICOLITICOS PRESINAPTICOS. tico, las mismas actúan básicamente de dos maneras diferentes: a.Axoplasmáticos: I- Inhiben la liberación de las catecolaminas en *Reserpina (Serpasol) la terminación adrenérgica, actuando a nivel Deserpidina presináptico y Rescinamina Guanetidina (Ismelin) II- Bloquean los receptores adrenérgicos en Batanidina las células efectoras a nivel postsináptico. Debrisoquina (Declinax,Sintiapress) Bretilio Las primeras son drogas simpaticolíticas que IMAO:Pargilina (Eutonil;Tranilcipromina (Parna- inhiben la síntesis de catecolaminas. Interfie- te) ren con los proceso de depósito y liberación de las mismas. Algunas actúan a nivel central reduciendo la activi dad simpática cerebral. b.Agonistas alfa 2:(Adrenoliticas de accion Este grupo de fármacos son los llam ados central) Simpaticolíticos presinápticos. Los simpati- colíticos postsinápticos son los bloqueantes Clonidina (Catapresan) de los receptores alfa y beta adrenérgicos. *Alfa-metil-dopa (Aldomet) Guanabenz (Rexitene) Todos estos agentes adrenolíticos son drogas Guanfacina (Estulic,Hipertensal) de gran utilidad terapéutica, capaces de gene- rar una solución farmacológica a numerosos padecimientos clínicos, principalmente en el II.SIMPATICOLITICOS POSTSINAPTICOS área cardiovascular.
    [Show full text]
  • New Concepts in Pharmacological Efficacy at 7TM Receptors: IUPHAR
    British Journal of DOI:10.1111/j.1476-5381.2012.02223.x www.brjpharmacol.org BJP Pharmacology Dr Terry Kenakin, University of International Union of Basic North Carolina, Pharmacology, Chapel Hill, North Carolina, and Clinical Pharmacology United States, Phone: 919-962-7863, Fax: 919 966 7242 Review or 5640, [email protected] ---------------------------------------------------------------- Keywords receptor theory; agonism; New concepts in efficacy; drug discovery ---------------------------------------------------------------- Received pharmacological efficacy at 8 May 2012 Revised 3 August 2012 7TM receptors: IUPHAR Accepted Review 2 12 September 2012 This is the second in a series of reviews written by committees Terry Kenakin of experts of the Nomenclature Committee of the International Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, Union of Basic and Clinical USA Pharmacology (NC-IUPHAR). A listing of all articles in the series and the Nomenclature Reports from IUPHAR published in Pharmacological Reviews can be found at http://www. GuideToPharmacology.org. This website, created in a The present-day concept of drug efficacy has changed completely from its original collaboration between the British Pharmacological Society description as the property of agonists that causes tissue activation. The ability to (BPS) and the International visualize the multiple behaviours of seven transmembrane receptors has shown that Union of Basic and Clinical drugs can have many efficacies and also that the transduction of drug stimulus to Pharmacology (IUPHAR), various cellular stimulus–response cascades can be biased towards some but not all is intended to become a pathways. This latter effect leads to agonist ‘functional selectivity’, which can be “one-stop shop” source of favourable for the improvement of agonist therapeutics.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Discovery of Β-Arrestin-Biased Β2-Adrenoceptor Agonists from 2-Amino-2-Phenylethanol Derivatives
    www.nature.com/aps ARTICLE Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives Anthony Yiu-Ho Woo1,2, Xin-yue Ge3,4,LiPan3,4, Gang Xing3,4, Yong-mei Mo3,4, Rui-juan Xing3,4,9, Xiao-ran Li1, Yu-yang Zhang1, Irving W. Wainer5,6, Mao-sheng Cheng3,4 and Rui-ping Xiao2,7,8 β-Arrestins are a small family of proteins important for signal transduction at G protein-coupled receptors (GPCRs). β-Arrestins are involved in the desensitization of GPCRs. Recently, biased ligands possessing different efficacies in activating the G protein- versus the β-arrestin-dependent signals downstream of a single GPCR have emerged, which can be used to selectively modulate GPCR signal transduction in such a way that desirable signals are enhanced to produce therapeutic effects while undesirable signals of the same GPCR are suppressed to avoid side effects. In the present study, we evaluated agonist bias for compounds developed along a drug discovery project of β2-adrenoceptor agonists. About 150 compounds, including derivatives of fenoterol, 2-amino-1- phenylethanol and 2-amino-2-phenylethanol, were obtained or synthesized, and initially screened for their β-adrenoceptor- mediated activities in the guinea pig tracheal smooth muscle relaxation assay or the cardiomyocyte contractility assay. Nineteen bioactive compounds were further assessed using both the HTRF cAMP assay and the PathHunter β-arrestin assay. Their concentration-response data in stimulating cAMP synthesis and β-arrestin recruitment were applied to the Black–Leff operational model for ligand bias quantitation. As a result, three compounds (L-2, L-4, and L-12) with the core structure of 5-(1-amino-2- hydroxyethyl)-8-hydroxyquinolin-2(1H)-one were identified as a new series of β-arrestin-biased β2-adrenoceptor agonists, whereas salmeterol was found to be Gs-biased.
    [Show full text]
  • 3- and J82-Adrenergic Receptors in Rat Brain (Norepinephrine/Epinephrine/'2,5-Labeled Pindolol/Ultrofflm)
    Proc. Natl. Acad. Sci. USA Vol. 81, pp. 1585-1589, March 1984 Neurobiology Quantitative autoradiography of !,3- and j82-adrenergic receptors in rat brain (norepinephrine/epinephrine/'2,5-labeled pindolol/Ultrofflm) THOMAS C. RAINBOW, BRUCE PARSONS, AND BARRY B. WOLFE Department of Pharmacology/G3, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Communicated by Louis B. Flexner, November 21, 1983 ABSTRACT We have used quantitative autoradiography dards, the optical density readings can be quantitatively con- to localize in rat brain /3i- and .82-adrenergic receptors. These verted to amount of radioligand bound per mg of protein receptors were labeled in vitro with 1251-labeled pindolol, an (11). Thus, in the present study we have combined the tech- antagonist of 13-adrenergic receptors that binds nonselectively niques of quantitative autoradiography and quantitative analy- to both .p2 and #2 subtypes. The selective inhibition of 1251_ sis of -adrenergic receptor subtypes to allow determination labeled pindolol binding with specific antagonists of .BI and 132 of subtype densities with a resolution of =100 Am. These receptors allowed the visualization of 18-adrenergic receptor studies, in addition to confirming the previous reports on the subtypes. High levels of ,B1 receptors were observed in the cin- distribution of subtypes in gross areas, such as the entire gulate cortex, layers I and II of the cerebral cortex, the hippo- cerebral cortex or cerebellum, have also disclosed that 381 campus, the Islands of Calleja, and the gelatinosus, mediodor- and 832 receptors are distributed heterogeneously among afa- sal, and ventral nuclei of the thalamus. High levels of #82 recep- tomically discrete nuclei and subregions of rat brain.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • ( 12 ) United States Patent
    US010493080B2 (12 ) United States Patent (10 ) Patent No.: US 10,493,080 B2 Schultz et al. (45 ) Date of Patent : Dec. 3 , 2019 ( 54 ) DIRECTED DIFFERENTIATION OF (56 ) References Cited OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE U.S. PATENT DOCUMENTS 7,301,071 B2 11/2007 Zheng (71 ) Applicants : The Scripps Research Institute , La 7,304,071 B2 12/2007 Cochran et al. Jolla , CA (US ) ; Novartis AG , Basel 9,592,288 B2 3/2017 Schultz et al. 2003/0225072 A1 12/2003 Welsh et al. ( CH ) 2006/0258735 Al 11/2006 Meng et al. 2009/0155207 Al 6/2009 Hariri et al . (72 ) Inventors : Peter Schultz , La Jolla , CA (US ) ; Luke 2010/0189698 A1 7/2010 Willis Lairson , San Diego , CA (US ) ; Vishal 2012/0264719 Al 10/2012 Boulton Deshmukh , La Jolla , CA (US ) ; Costas 2016/0166687 Al 6/2016 Schultz et al. Lyssiotis , Boston , MA (US ) FOREIGN PATENT DOCUMENTS (73 ) Assignees : The Scripps Research Institute , La JP 10-218867 8/1998 Jolla , CA (US ) ; Novartis AG , Basel JP 2008-518896 5/2008 (CH ) JP 2010-533656 A 10/2010 WO 2008/143913 A1 11/2008 WO 2009/068668 Al 6/2009 ( * ) Notice : Subject to any disclaimer , the term of this WO 2009/153291 A1 12/2009 patent is extended or adjusted under 35 WO 2010/075239 Al 7/2010 U.S.C. 154 ( b ) by 0 days . (21 ) Appl. No .: 15 /418,572 OTHER PUBLICATIONS Molin - Holgado et al . “ Regulation of muscarinic receptor function in ( 22 ) Filed : Jan. 27 , 2017 developing oligodendrocytes by agonist exposure ” British Journal of Pharmacology, 2003 , 138 , pp .
    [Show full text]